AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01661751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A+C Meningococcal Polysaccharide Vaccine
Description: 300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
Study NCT05128864 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: High Tibial Osteotomy
Description: Surgery procedure - High Tibial Osteotomy
Study NCT05128864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Tibial Osteotomy
Description: Surgery procedure - High Tibial Osteotomy
Study NCT01251991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isolated whey protein
Description: Oral suspension, oral use, 30 grams once per day
Study NCT01251991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Study NCT01251991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Study NCT04281823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance
Description: Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
Study NCT04476108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV
Study NCT04476108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02448095 — intervention group
Intervention type: DRUG
Intervention: Ponatinib
Description: Observation of tolerability and safety profiles
Study NCT00397631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
Description: Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
Study NCT00397631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
Description: Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
Study NCT02213081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal
Description: Patient will take 15mg every other day, or every 4 days per week.
Study NCT00471276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib (Sutent), 37.5 mg, daily dosing
Study NCT03542292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: placental drainage
Study NCT03542292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: placental drainage
Study NCT00717951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxol, cisplatin, capecitabine
Description: docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
Study NCT01537523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: community-care program
Description: community nurse care, physiotherapy
Study NCT00572065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.
Study NCT00572065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.
Study NCT02805894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBTXR3 activated by IMRT only
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
Study NCT02805894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBTXR3 activated by Brachytherapy & IMRT
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
Study NCT00952588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: 1200 mg, iv, 7 day infusion
Study NCT00952588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDAC
Description: 20 mg, sc, bd, 10 days
Study NCT00606229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg/day
Study NCT01110928 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
Study NCT04474366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
Study NCT04474366 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline (0.9%)
Description: Saline injection as sham block in identical fashion as Pectoralis Nerve Block
Study NCT03773601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Profiler
Description: A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
Study NCT03773601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSQI
Description: Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
Study NCT03773601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TQR
Description: Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
Study NCT02139280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
Study NCT02139280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
Study NCT01585909 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastroscopy
Description: When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
Study NCT01224730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: 100 mg daily
Study NCT02846766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
Study NCT01119924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smilon®
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
Study NCT00851318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Subcutaneous (SC) injection
Study NCT00851318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate dose between 6 to 8 mg/week.
Study NCT01119924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
Study NCT01833026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometry test
Description: For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
Study NCT01833026 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spirometry test
Description: For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
Study NCT01833026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
Study NCT01833026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol
Description: The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
Study NCT02755662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Retention Device
Study NCT04488601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin in 2 different dosage forms.
Study NCT04488601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT05480631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autograft
Description: autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
Study NCT05480631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autograft with addition of concenterated growth factor
Description: the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
Study NCT05480631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: xenograft with concentrated growth factor
Description: xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
Study NCT03801798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1102
Description: NAs antivirals+GC1102 180,000 IU
Study NCT01299792 — intervention group
Intervention type: OTHER
Intervention: sonographic measurement of bladder wall thickness
Description: measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
Study NCT00751751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary
Description: oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
Study NCT00751751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan + hydrochlorothiazide, if necessary
Description: oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
Study NCT03982628 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal CT imaging
Description: Routine abdominal CT imaging
Study NCT03801798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GC1102 Placebo
Description: NAs antivirals+GC1102 Placebo
Study NCT02021240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT01563406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 second scrub
Description: Scrub catheter hubs for 15 seconds before every access.
Study NCT03680066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral food challenge to foods with traces
Description: Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~* cookies, max 30 g;~* chocolate, max 30 g;~* breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end.
Study NCT01563406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 second scrub
Description: Scrub catheter hubs for 15 seconds before every access.
Study NCT01563406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.15% chlorhexidine/70% isopropyl alcohol
Description: 3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
Study NCT01563406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Description: 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
Study NCT03476928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2mg, once daily, oral
Study NCT03592589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal canula
Description: high flow nasal canula to obtain a positive expiratory pressure
Study NCT02325128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-enhancement of extinction memory
Description: Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
Study NCT02325128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep-enhancement of extinction memory
Description: Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
Study NCT01885104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG 3350)
Description: Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
Study NCT01885104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
Study NCT01885104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl laxative tablets (rescue medication)
Description: 5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
Study NCT04380766 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer
Description: Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
Study NCT03670693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle strength and fatigue assessment
Description: Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
Study NCT01885104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisacodyl laxative tablets (rescue medication)
Description: 5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
Study NCT00369928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 100 mg BID, of oral PG-760564
Study NCT04505319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEFINISSE CORE FILLER
Description: DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face
Study NCT01903122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cevimeline
Study NCT01720589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melt (test oil)
Study NCT01720589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn oil (control)
Study NCT00075764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Given orally
Study NCT00075764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally
Study NCT00075764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly
Study NCT02934841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Study NCT02934841 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Study NCT00842283 — intervention group
Intervention type: OTHER
Intervention: skin tissue sample
Description: skin tissue sample
Study NCT00819000 — intervention group
Intervention type: DRUG
Intervention: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
Description: MS therapies (listed above) used according to prescribers' instructions.
Study NCT04607174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pathologic group
Description: Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb.
Study NCT01482806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCBT+ISG/Collaborative Care
Description: Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference.
Study NCT01482806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCBT/Collaborative Care
Description: Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference.